18 F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study
Our objective was to assess the effect of F-DCFPyL prostate-specific membrane antigen (PSMA) positron emission tomography (PET) on the management and outcomes of patients receiving salvage radiotherapy following biochemical failure (BF) post-radical prostatectomy (RP) using a matched cohort analysis...
Gespeichert in:
| Veröffentlicht in: | Canadian Urological Association journal 2023-08, Vol.17 (8), p.247 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 247 |
| container_title | Canadian Urological Association journal |
| container_volume | 17 |
| creator | Arifin, Andrew J Gulstene, Stephanie Warner, Andrew Bauman, Glenn S Mendez, Lucas C |
| description | Our objective was to assess the effect of
F-DCFPyL prostate-specific membrane antigen (PSMA) positron emission tomography (PET) on the management and outcomes of patients receiving salvage radiotherapy following biochemical failure (BF) post-radical prostatectomy (RP) using a matched cohort analysis.
A PSMA-PET cohort of patients with BF post-RP was identified through a prospective registry. Patients from this registry were included if they did not have disease outside of the pelvis and underwent salvage radiotherapy to the prostate and/or pelvis. Case-control matching was performed with a contemporary cohort of patients with BF post-RP without PSMA-PET information.
Forty-four patients were included in the PSMA-PET cohort and 80 were analyzed in the non-PSMA-PET cohort. The PSMA-PET cohort had a significantly higher pre-radiotherapy median prostate-specific antigen (PSA) of 0.48 ng/mL compared to 0.20 ng/mL in the non-PSMA-PET cohort (p |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_37581539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37581539</sourcerecordid><originalsourceid>FETCH-pubmed_primary_375815393</originalsourceid><addsrcrecordid>eNqFT8GKwjAUzMFFXfUX5P1AoKFq1ZuoZQ-7UNC7PNvERhoTktdd8hd-sjnsnvcywwwzAzNgY7ERgq8WRTZi7yHcs2yVnGLIRnmxXItlvhmzp1hDyQ_7soqfUJ2-drw6ngGVkjUFMPjAmzTyQWAVBOy-kwSPjbbUSo8ugrIenA3EnU-IlHrWRHBIOtUC_Ghq4apt3Uqja-xAoe56L7ewS_OU7AZq21pPEKhv4pS9KeyCnP3yhM3L43n_wV1_NbK5OK8N-nj5u5D_G3gBaHpTMQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>18 F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Arifin, Andrew J ; Gulstene, Stephanie ; Warner, Andrew ; Bauman, Glenn S ; Mendez, Lucas C</creator><creatorcontrib>Arifin, Andrew J ; Gulstene, Stephanie ; Warner, Andrew ; Bauman, Glenn S ; Mendez, Lucas C</creatorcontrib><description>Our objective was to assess the effect of
F-DCFPyL prostate-specific membrane antigen (PSMA) positron emission tomography (PET) on the management and outcomes of patients receiving salvage radiotherapy following biochemical failure (BF) post-radical prostatectomy (RP) using a matched cohort analysis.
A PSMA-PET cohort of patients with BF post-RP was identified through a prospective registry. Patients from this registry were included if they did not have disease outside of the pelvis and underwent salvage radiotherapy to the prostate and/or pelvis. Case-control matching was performed with a contemporary cohort of patients with BF post-RP without PSMA-PET information.
Forty-four patients were included in the PSMA-PET cohort and 80 were analyzed in the non-PSMA-PET cohort. The PSMA-PET cohort had a significantly higher pre-radiotherapy median prostate-specific antigen (PSA) of 0.48 ng/mL compared to 0.20 ng/mL in the non-PSMA-PET cohort (p<0.001), but these levels were similar after matching. The PSMA-PET cohort had a higher proportion of patients receiving radiotherapy to pelvic lymph nodes (n=27 [61.4%] vs. n=16 [20.0%], p<0.001). Median followup was 26 months (interquartile range 18.8-33) for both cohorts. BF-free survival and event-free survival were not significantly different between the two cohorts for all (p=0.662 and >0.99) and matched patients (p=0.808 and 0.808), respectively. Metastasis-free survival was significantly higher in the matched PSMA-PET cohort compared to the matched non-PSMA-PET cohort (p=0.046), although a higher proportion of patients in the non-PSMA-PET cohort underwent PSMA-PET restaging after BF (52% vs. 20%, p=0.08726).
Our study showed that patients undergoing PSMA-PET scans after BF post-RP had a higher likelihood of pelvic nodal treatment at the time of salvage RT. Despite higher PSA levels at salvage, we identified no recurrence or survival differences.</description><identifier>ISSN: 1911-6470</identifier><identifier>PMID: 37581539</identifier><language>eng</language><publisher>Canada</publisher><ispartof>Canadian Urological Association journal, 2023-08, Vol.17 (8), p.247</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37581539$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arifin, Andrew J</creatorcontrib><creatorcontrib>Gulstene, Stephanie</creatorcontrib><creatorcontrib>Warner, Andrew</creatorcontrib><creatorcontrib>Bauman, Glenn S</creatorcontrib><creatorcontrib>Mendez, Lucas C</creatorcontrib><title>18 F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study</title><title>Canadian Urological Association journal</title><addtitle>Can Urol Assoc J</addtitle><description>Our objective was to assess the effect of
F-DCFPyL prostate-specific membrane antigen (PSMA) positron emission tomography (PET) on the management and outcomes of patients receiving salvage radiotherapy following biochemical failure (BF) post-radical prostatectomy (RP) using a matched cohort analysis.
A PSMA-PET cohort of patients with BF post-RP was identified through a prospective registry. Patients from this registry were included if they did not have disease outside of the pelvis and underwent salvage radiotherapy to the prostate and/or pelvis. Case-control matching was performed with a contemporary cohort of patients with BF post-RP without PSMA-PET information.
Forty-four patients were included in the PSMA-PET cohort and 80 were analyzed in the non-PSMA-PET cohort. The PSMA-PET cohort had a significantly higher pre-radiotherapy median prostate-specific antigen (PSA) of 0.48 ng/mL compared to 0.20 ng/mL in the non-PSMA-PET cohort (p<0.001), but these levels were similar after matching. The PSMA-PET cohort had a higher proportion of patients receiving radiotherapy to pelvic lymph nodes (n=27 [61.4%] vs. n=16 [20.0%], p<0.001). Median followup was 26 months (interquartile range 18.8-33) for both cohorts. BF-free survival and event-free survival were not significantly different between the two cohorts for all (p=0.662 and >0.99) and matched patients (p=0.808 and 0.808), respectively. Metastasis-free survival was significantly higher in the matched PSMA-PET cohort compared to the matched non-PSMA-PET cohort (p=0.046), although a higher proportion of patients in the non-PSMA-PET cohort underwent PSMA-PET restaging after BF (52% vs. 20%, p=0.08726).
Our study showed that patients undergoing PSMA-PET scans after BF post-RP had a higher likelihood of pelvic nodal treatment at the time of salvage RT. Despite higher PSA levels at salvage, we identified no recurrence or survival differences.</description><issn>1911-6470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFT8GKwjAUzMFFXfUX5P1AoKFq1ZuoZQ-7UNC7PNvERhoTktdd8hd-sjnsnvcywwwzAzNgY7ERgq8WRTZi7yHcs2yVnGLIRnmxXItlvhmzp1hDyQ_7soqfUJ2-drw6ngGVkjUFMPjAmzTyQWAVBOy-kwSPjbbUSo8ugrIenA3EnU-IlHrWRHBIOtUC_Ghq4apt3Uqja-xAoe56L7ewS_OU7AZq21pPEKhv4pS9KeyCnP3yhM3L43n_wV1_NbK5OK8N-nj5u5D_G3gBaHpTMQ</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Arifin, Andrew J</creator><creator>Gulstene, Stephanie</creator><creator>Warner, Andrew</creator><creator>Bauman, Glenn S</creator><creator>Mendez, Lucas C</creator><scope>NPM</scope></search><sort><creationdate>202308</creationdate><title>18 F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study</title><author>Arifin, Andrew J ; Gulstene, Stephanie ; Warner, Andrew ; Bauman, Glenn S ; Mendez, Lucas C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_375815393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arifin, Andrew J</creatorcontrib><creatorcontrib>Gulstene, Stephanie</creatorcontrib><creatorcontrib>Warner, Andrew</creatorcontrib><creatorcontrib>Bauman, Glenn S</creatorcontrib><creatorcontrib>Mendez, Lucas C</creatorcontrib><collection>PubMed</collection><jtitle>Canadian Urological Association journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arifin, Andrew J</au><au>Gulstene, Stephanie</au><au>Warner, Andrew</au><au>Bauman, Glenn S</au><au>Mendez, Lucas C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>18 F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study</atitle><jtitle>Canadian Urological Association journal</jtitle><addtitle>Can Urol Assoc J</addtitle><date>2023-08</date><risdate>2023</risdate><volume>17</volume><issue>8</issue><spage>247</spage><pages>247-</pages><issn>1911-6470</issn><abstract>Our objective was to assess the effect of
F-DCFPyL prostate-specific membrane antigen (PSMA) positron emission tomography (PET) on the management and outcomes of patients receiving salvage radiotherapy following biochemical failure (BF) post-radical prostatectomy (RP) using a matched cohort analysis.
A PSMA-PET cohort of patients with BF post-RP was identified through a prospective registry. Patients from this registry were included if they did not have disease outside of the pelvis and underwent salvage radiotherapy to the prostate and/or pelvis. Case-control matching was performed with a contemporary cohort of patients with BF post-RP without PSMA-PET information.
Forty-four patients were included in the PSMA-PET cohort and 80 were analyzed in the non-PSMA-PET cohort. The PSMA-PET cohort had a significantly higher pre-radiotherapy median prostate-specific antigen (PSA) of 0.48 ng/mL compared to 0.20 ng/mL in the non-PSMA-PET cohort (p<0.001), but these levels were similar after matching. The PSMA-PET cohort had a higher proportion of patients receiving radiotherapy to pelvic lymph nodes (n=27 [61.4%] vs. n=16 [20.0%], p<0.001). Median followup was 26 months (interquartile range 18.8-33) for both cohorts. BF-free survival and event-free survival were not significantly different between the two cohorts for all (p=0.662 and >0.99) and matched patients (p=0.808 and 0.808), respectively. Metastasis-free survival was significantly higher in the matched PSMA-PET cohort compared to the matched non-PSMA-PET cohort (p=0.046), although a higher proportion of patients in the non-PSMA-PET cohort underwent PSMA-PET restaging after BF (52% vs. 20%, p=0.08726).
Our study showed that patients undergoing PSMA-PET scans after BF post-RP had a higher likelihood of pelvic nodal treatment at the time of salvage RT. Despite higher PSA levels at salvage, we identified no recurrence or survival differences.</abstract><cop>Canada</cop><pmid>37581539</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1911-6470 |
| ispartof | Canadian Urological Association journal, 2023-08, Vol.17 (8), p.247 |
| issn | 1911-6470 |
| language | eng |
| recordid | cdi_pubmed_primary_37581539 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| title | 18 F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A26%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=18%20F-DCFPyL%20PSMA-PET%20affects%20management%20of%20salvage%20radiotherapy%20for%20post-prostatectomy%20patients%20with%20biochemical%20failure:%20A%20matched%20cohort%20study&rft.jtitle=Canadian%20Urological%20Association%20journal&rft.au=Arifin,%20Andrew%20J&rft.date=2023-08&rft.volume=17&rft.issue=8&rft.spage=247&rft.pages=247-&rft.issn=1911-6470&rft_id=info:doi/&rft_dat=%3Cpubmed%3E37581539%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37581539&rfr_iscdi=true |